Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +46.40%
#2 Pons Pons +33.09%
#3 TENDIES TENDIES +31.51%
#4 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +29.78%
#5 Starpower Starpower +28.97%
#6 StonkBroker StonkBroker +23.95%
#7 SkyAI SkyAI +22.66%
#8 Mubarak Mubarak +22.28%
#9 PondCoin PondCoin +21.09%
#10 Ocean Protocol Ocean Protocol +19.89%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
設定
言語
日本
通貨
USD
テーマ
Celularity Inc. Celularity Inc.

Celularity Inc.

CELU
株式のランク #28923
Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to... Celularity Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering "off-the-shelf" allogeneic cell therapies, which are developed from placental sources. These innovative treatments are designed to combat a range of serious conditions, including various cancers, immune system dysfunctions, and infectious diseases. The company’s operations are segmented into three distinct areas: Cell Therapy, Degenerative Disease, and BioBanking. Their therapeutic pipeline features several key candidates: CYCART-19, a placental-derived CAR-T therapy, currently in Phase I trials for B-cell malignancies; CYNK-001, an unmodified natural killer (NK) cell also from placental sources, advancing through Phase I trials for acute myeloid leukemia and Phase I/IIa trials for glioblastoma multiforme and COVID-19; and CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I for HER2+ gastric and gastroesophageal cancers. Furthermore, two mesenchymal-like adherent stromal cell candidates, APPL-001 and PDA-002 (both derived from placentas), are in pre-clinical development for Crohn's disease and facioscapulohumeral muscular dystrophy, respectively. In addition to its therapeutic development, Celularity is involved in commercial activities, offering surgical and wound care products like Biovance and Interfyl through sales and licensing agreements. The company also specializes in collecting stem cells from umbilical cords and placentas, providing storage services under its LifebankUSA brand. Founded in 2016, Celularity Inc. maintains its headquarters in Florham Park, New Jersey.
株価
$0.8353
時価総額
$24.18M
変化（1日）
13.38%
変化（1年）
-76.86%
国
US
取引 Celularity Inc. (CELU)

カテゴリー

Healthcare
Celularity Inc.（CELU）の利益
2026 時点の利益 TTM: 0
Celularity Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Celularity Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
$1.61B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH